UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------
FORM 8-K/A
Amendment No. 1
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) February 24, 2003
-------------
INTEGRATED BIOPHARMA INC.
(formerly INTEGRATED HEALTH TECHNOLOGIES, INC.)
(Exact Name of Registrant as Specified in Charter)
Delaware 000-28876 22-2407475
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
201Route 22, Hillside, New Jersey 07205
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (973) 926-0816
-------------
NOT APPLICABLE
(Former Name or Former Address, if Changed Since Last Report)
1
This Current Report on Form 8-K/A (Amendment No. 1) amends the Current Report on
Form 8-K filed with the Securities and Exchange Commission on February 26, 2003
by Integrated Health Technologies, Inc. (the "Company") relating to the
acquisition by the Company of the membership interests of Natex Georgia LLC from
Trade Investment Services, L.L.C. (the "Natex Acquisition").
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(a) Financial Statements
The Company has determined that no financial statements are required to be
filed with this report in connection with the Natex Acquisition which was
not deemed to involve a significant amount of assets.
(b) Pro Forma Financial Information
The Company has determined that no pro forma financial information is
required to be filed with this report in connection with the Natex
Acquisition which was not considered significant.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
INTEGRATED BIOPHARMA, INC.
Date: April 24, 2003 By: /s/ Seymour Flug
---------------------------
Name: Seymour Flug
Title: President